Boston - American Association for Thoracic Surgery

More documents

Recommendations

Info

89 TH ANNUAL MEETING MAY 9–MAY 13, 2009BOSTON, MASSACHUSETTStumor control in IB disease (p = 0.893). In patients < 75 years old, 3-year diseasespecific survival was 85% with surgery and 60% with SBRT (p = 0.013), with nosurvival difference in patients >75 (p = 0.14). In clinical stage IA patients, 3-yeardisease specific survival with surgery was 85% vs. 71% with SBRT (p = 0.04). Nodisease specific survival differences were found in patients with IB disease (p =0.69). Table 1 summarizes the regression analysis comparing local tumor controland survival between surgery and SBRT matched by age, comorbidity score, andtumor stage.CONCLUSION: In an unmatched comparison surgical patients were generallyhealthier and had better local tumor control and disease-specific survival in clinicalstage IA vs. SBRT patients. Propensity regression analysis in clinical stage IA/BNSCLC revealed equivocal local recurrence and disease-specific survival betweensurgery and SBRT.100
AMERICAN ASSOCIATION FOR THORACIC SURGERY17. NETT REDUX (Accentuating the Positive)Pablo G. Sanchez, John C. Kucharczuk, Stacey Su, Larry R. Kaiser, * Joel D. Cooper *Department of Surgery, Division of Thoracic Surgery, University of Pennsylvania,Philadelphia, PA, USAInvited Discussant: Rodney J. LandreneauOBJECTIVE: The National Emphysema Treatment Trial (NETT), a randomizedclinical trial, was designed to determinate whether or not bilateral lung volumereduction surgery (LVRS) was more effective than medical management (controlgroup) for selected patients with severe emphysema. A series of arbitrary thresholdsfor improvement were applied equally to both groups and demonstrated staticallysignificant benefit for LVRS patients in terms of exercise capacity, increase in FEV1and improvement in health related quality of life (p ≤ .001 for each comparison).The established pre-trial hypothesis was that emphysema patients who have “heterogeneouslydistributed emphysema involving the upper lung zones predominantly”would be most likely to benefit from LVRS. However NETT accrualcriteria “were crafted to include all patients who might benefit from LVRS” andtherefore included many patients who did not fit the hypothesis. The purpose ofthis paper is to analyze the outcome of LVRS for the subgroup of patients who metthe original NETT hypothesis and to determine the magnitude and duration ofbenefit for this subgroup.MONDAYAfternoonMETHODS: Under the Freedom of Information Act, we received and analyzed theNETT data set as of May 2006.RESULTS: Between January 1998 and July 2002, 571 patients received bilateralLVRS and 562 patients received medical therapy within the trial. Two hundred andsixty one of the LVRS patients (46%) and 250 of the medical therapy patients(44%) met the NETT criteria for heterogeneously distributed upper lobe predominantdisease. The 90 day mortality rate for the LVRS group was 5% (13 patients)and for the medical group 1.6% (4 patients). Subsequent mortality at 6 months was1.5% for the LVRS group and 1.2% for the medical group and at 24 months 7.6% forLVRS and 13.6% for the medical group. Mortality data was complete but the percentageof LVRS and medical patients with missing objective data was 8% and24% at 6 months; 25% and 42% at 24 months; and 45% and 61% at 36 monthsrespectively. Results in terms of FEV1, Residual Volume (RV), 6 minute walk anddyspnea score are shown in the following table.CONCLUSION: For patients with upper lobe predominant emphysema, LVRSprovided both statistically and functionally significant improvement in exercisetolerance, measured lung function, dyspnea score and quality of life. These resultsconfirm the hypothesis of the NETT trial and also confirm the results of othernon-randomized reports as to the value of LVRS in appropriately selected patients.* AATS Member101
Page 1 and 2:
American Associationfor Thoracic Su
Page 3 and 4:
AMERICAN ASSOCIATION FOR THORACIC S
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52: AMERICAN ASSOCIATION FOR THORACIC S
Page 101: AMERICAN ASSOCIATION FOR THORACIC S
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 227 and 228:
AATS FUTURE MEETINGSMay 1-5, 2010Me
show all

Boston - American Association for Thoracic Surgery

Create successful ePaper yourself

Delete template?

Save as template?